To further investigate whether low MATH value in FGFR3-mutant patients is widely applicable to predict better overall survival in BLCA, we selected another BLCA cohort which was composed of 109 bladder cancer patients published in 2015 [24]. This evidence concerns the gene FGFR3 and urinary bladder carcinoma.